Frank Hazevoets

Chief Executive Officer bei DMS IMAGING

57 Jahre

Health Technology

Consumer Non-Durables

Consumer Services

Aktive Positionen von Frank Hazevoets

Unternehmen	Position	Beginn	Ende
DMS IMAGING	Director/Board Member	02.05.2019	-
	Chief Executive Officer	13.10.2020	-
	Director of Finance/CFO	01.01.2020	-
	Investor Relations Contact	01.04.2019	-

Unternehmen	Position	Beginn	Ende
PROMETHERA Biosciences SA PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.	Director of Finance/CFO	01.05.2014	05.10.2018
TIGENIX NV	Director of Finance/CFO	01.01.2006	01.01.2012
TIGENIX NV	Corporate Secretary	01.01.2006	01.01.2012
InBev SA	Corporate Officer/Principal	01.01.2001	01.01.2006
Smeets Securities BV	Corporate Officer/Principal	-	-
Puilaetco	Corporate Officer/Principal	-	-

Université Catholique de Louvain

Graduate Degree

International

Belgien	7
	2

Operativ

Director of Finance/CFO	3
Corporate Officer/Principal	3
Corporate Secretary	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
DMS IMAGING	Health Technology

Private Unternehmen	5
InBev SA	Consumer Non-Durables
TiGenix NV TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium.	Health Technology
Smeets Securities BV
PROMETHERA Biosciences SA PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.	Health Technology
Puilaetco	Finance